Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Soligenix Aims To Push The Boundaries In Treating Rare Diseases

February 25, 2025 at 11:30 AM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

By Johnny Rice Benzinga

DETROIT, MICHIGAN - February 25, 2025 (NEWMEDIAWIRE) - Christopher J. Schaber, Ph.D, president and CEO of Soligenix Inc. (NASDAQ: SNGX), was recently a guest on Benzinga’s All-Access.

Soligenix, a late-stage biopharmaceutical company, is focused on developing and commercializing treatments for rare diseases. The company's key focus is on HyBryte(TM), a novel photodynamic therapy for cutaneous T-cell lymphoma, and the expansion of synthetic hypericin into psoriasis and other inflammatory diseases.

Schaber shared exciting updates from the company’s phase 3 study of HyBryte. Preliminary results are expected in mid 2026.

Watch the full interview here: https://youtu.be/qs6MxADPsAA

Featured photo by Online Marketing on Unsplash.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

This content was originally published on Benzinga. Read further disclosures here.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article